EU consults on future of project for accelerating trials in developing countries
This article was originally published in Scrip
The European Commission is seeking feedback on the future of an R&D programme that was set up to accelerate the development of new and improved drugs against HIV/AIDS, malaria and tuberculosis. The programme's current focus is on conducting Phase II and III clinical trials in Sub-Saharan Africa.
You may also be interested in...
Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy.
EU guidance offers high-level recommendations on the steps that clinical trial sponsors should take to assess the impact of COVID-19 on the quality and reliability of data being generated in ongoing studies. Early scientific advice is recommended if changes must be made to existing protocols or data analysis plans.
The COVID-19 pandemic has given a fresh impetus to the ongoing EU project on remote decentralized trials with more appetite for innovative approaches.